News
Media
Between the LinesExpert InterviewsK-CastMedical World NewsPodcastsPopulation Health Perspectives
Conferences
Partners
More
Publications
All PublicationsMHE PublicationFormulary Watch SupplementsFormulary Watch SpotlightsSupplements And Featured Publications
Events
Webinars
CME/CE
Resources
PBMI InnovatorsEmerging LeadersInteractive ToolsSponsored Content
PBM Directory

Subscribe

  • News
  • Media
  • Conferences
  • Partners
  • Publications
  • Events
  • CME/CE
  • Resources
  • PBM Directory
  • Subscribe
  • Asthma
  • Atrial Fibrillation
  • Autoimmune Diseases
  • Biologics
  • Biosimilars
  • Blood Cancer
  • Breast Cancer
  • COVID-19
  • Cardiovascular Diseases
  • Depression
  • Dermatology
  • Diabetes
  • Digital Health
  • Drug Coverage
  • Duchenne Muscular Dystrophy
  • Eyecare
  • FDA
  • Friedreich Ataxia
  • Gene Therapy
  • Graft Versus Host Disease
  • HIV
  • Health Systems
  • Heart Failure
  • Hemophilia
  • Hypertrophic Cardiomyopathy (HCM)
  • Infectious Disease
  • Leukemia and Lymphoma
  • Liver Disease
  • Lung Cancer
  • Mental Health
  • Multiple Sclerosis
  • NSCLC
  • Neonatal Care
  • Nephrology
  • Obstetrics-Gynecology & Women's Health
  • Oncology
  • Oncology Biomarkers
  • Opioids
  • PTSD
  • Pain
  • Pediatrics
  • Plaque Psoriasis
  • Population Health
  • Post-Acute Care
  • Prescription Digital Therapeutics
  • Pulmonary Arterial Hypertension
  • RSV
  • Reproductive Health
  • Respiratory Conditions
  • Safety & Recalls
  • Schizophrenia
  • Shingles
  • Skin Cancer
  • Sleep Disorders
  • Solid Tumors
  • Spinal Muscular Atrophy
  • Substance Use Disorder
  • The Improving Patient Access Podcast
  • Type I Diabetes
  • Type II Inflammation
  • Ulcerative Colitis
  • Uro-Oncology
  • Urothelial Carcinoma
  • Vaccines
  • Women's Health
Spotlight -
AAO 2025|
PBMI 2025|
ASRS 2025|
IAS 2025|
K-Cast: Optimizing Narcolepsy Care
Advertisement

Robert Rouse, Head of US Market Access, CSL Behring

Advertisement

Articles by Robert Rouse, Head of US Market Access, CSL Behring

The value of Innovative Medicine: The clinical and economic impact of the first gene therapy for hemophilia B

ByAmbrose Carrejo, PharmD ,Pharmaceutical Contracting Leader, Kaiser Permanente (retired),Robert Rouse, Head of US Market Access, CSL Behring
November 27th 2023
Advertisement

Latest Updated Articles



    Advertisement
    Advertisement

    Trending on Managed Healthcare Executive

    1

    Sponsored: The Teva Biosimilars Trend Report

    2

    California PBM Law is a Starting Point for Real Transparency

    3

    Topical Ruxolitinib Cream Rapidly Repigments Vitiligo Lesions, Study Finds

    4

    FDA Accepts NDA for Investigational Maintenance Asthma Treatment

    5

    WHO Global Report on Antimicrobial Resistance Sheds Light on Growing Threat

    • About Us
    • Advertise
    • Editorial
    • Contact Us
    • Terms and Conditions
    • Privacy
    • Do Not Sell My Personal Information
    Contact Info

    259 Prospect Plains Rd, Bldg H
    Cranbury, NJ 08512

    609-716-7777

    • Formulary Watch
    • Pharmacy Benefit Management Institute
    Managed Healthcare Executive
    Brand Logo

    © 2025 MJH Life Sciences®

    All rights reserved.

    Home
    About Us
    News
    Contact Us